Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
UPDATE: Amgen axes an obesity asset, zooms in on MariTide
Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide.
Gabrielle Masson
May 2, 2024 6:16pm
Regeneron, Lilly grapple with clinical endpoints in obesity
May 2, 2024 10:38am
Lilly uses Mounjaro millions to hunt for biotech partners
May 1, 2024 9:26am
Arch-backed obesity biotech launches with $290M
Apr 18, 2024 7:00am
FDA aims to boost trial innovation with new center at CDER
Apr 17, 2024 10:03am
Lilly's Prevail walks away from Precision gene editing collab
Apr 17, 2024 8:48am